Scarica l'app Stockscreener
2.04
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.04
Aprire:
$2.05
Volume 24 ore:
130.09K
Relative Volume:
0.19
Capitalizzazione di mercato:
$65.07M
Reddito:
-
Utile/perdita netta:
$-98.79M
Rapporto P/E:
-0.6239
EPS:
-3.27
Flusso di cassa netto:
$-51.66M
1 W Prestazione:
-1.92%
1M Prestazione:
+28.30%
6M Prestazione:
+590.36%
1 anno Prestazione:
-38.37%
Intervallo 1D:
$1.92
$2.08
Intervallo di 1 settimana:
$1.92
$2.27
Portata 52W:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Confronta RLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.70 | 5.31B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.55 | 113.25M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.2028 | 445.05M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.05 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Why Relmada Therapeutics Inc. stock is a value investor pickJuly 2025 Chart Watch & Free Technical Pattern Based Buy Signals - newser.com
Reversal indicators forming on Relmada Therapeutics Inc. stockEarnings Growth Report & High Accuracy Swing Trade Signals - newser.com
Will Relmada Therapeutics Inc. stock recover faster than marketPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com
Combining machine learning predictions for Relmada Therapeutics Inc.Market Performance Recap & Stock Timing and Entry Methods - newser.com
Relmada seeking strategic options, stock climbs 5% - MSN
Relmada Therapeutics (NASDAQ:RLMD) Upgraded at Wall Street Zen - Defense World
D pipelineWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Relmada Therapeutics (NASDAQ:RLMD) - MarketBeat
Relmada appoints Johns Hopkins professor to clinical advisory board - Investing.com
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 - Investing News Network
Relmada Therapeutics, Inc. Appoints Distinguished Urologic Oncologist, Max Kates, Md, to the Clinical Advisory Board - MarketScreener
Relmada appoints Johns Hopkins professor to clinical advisory board By Investing.com - Investing.com Australia
Relmada Therapeutics appoints Max Kates, MD, to the clinical advisory board to support development of NDV-01 - MarketScreener
Relmada Therapeutics Appoints Dr. Max Kates to Clinical Advisory Board to Support NDV-01 Phase 3 Program for Bladder Cancer - Quiver Quantitative
Phase 3 H1 2026 — Relmada Taps Max Kates to Guide NDV-01 for NMIBC, Bringing BRIDGE Trial Expertise - Stock Titan
Why Relmada Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Verified Technical Trade Signals - newser.com
Using data tools to time your Relmada Therapeutics Inc. exit2025 Trading Recap & Weekly Watchlist for Hot Stocks - newser.com
Is Relmada Therapeutics Inc. (4E2) stock undervalued at current pricePortfolio Update Report & Low Drawdown Investment Strategies - newser.com
Earnings visualization tools for Relmada Therapeutics Inc.July 2025 Market Mood & Technical Pattern Recognition Alerts - newser.com
Relmada Therapeutics Inc. stock retracement – recovery analysis2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
Using data filters to optimize entry into Relmada Therapeutics Inc.July 2025 Price Swings & Free Expert Approved Momentum Trade Ideas - newser.com
What drives Relmada Therapeutics Inc stock priceBlue Chip Stock Analysis & Investment Timing Techniques - earlytimes.in
Promising Penny Stocks To Watch In October 2025 - Yahoo Finance
Goldman Sachs Group Inc. Invests $33,000 in Relmada Therapeutics, Inc. $RLMD - Defense World
Using Python tools to backtest Relmada Therapeutics Inc. strategiesEarnings Beat & High Accuracy Swing Trade Signals - newser.com
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relmada Therapeutics Inc Azioni (RLMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
| Kelly Paul Edward | Chief Operating Officer |
May 16 '25 |
Buy |
0.43 |
200,000 |
86,060 |
412,295 |
| Shenouda Maged | Chief Financial Officer |
May 19 '25 |
Buy |
0.49 |
90,000 |
43,686 |
228,335 |
| Shenouda Maged | Chief Financial Officer |
May 20 '25 |
Buy |
0.52 |
60,000 |
31,422 |
288,335 |
| Shenouda Maged | Chief Financial Officer |
May 16 '25 |
Buy |
0.44 |
50,000 |
22,100 |
138,335 |
| Ence Chuck | CA and CO |
May 16 '25 |
Buy |
0.45 |
228,961 |
103,330 |
267,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 20 '25 |
Buy |
0.56 |
147,686 |
82,246 |
734,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 16 '25 |
Buy |
0.45 |
172,314 |
77,472 |
556,338 |
| TRAVERSA SERGIO | Chief Executive Officer |
May 19 '25 |
Buy |
0.50 |
30,000 |
14,994 |
586,338 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):